Some choose off-label drug to treat macular degeneration

09/22/2006 | Miami Herald (free registration), The

While a new drug called Lucentis has been approved by the FDA to restore vision to people with macular degeneration, many doctors are using a similar drug, Avastin, off-label. That's because Avastin costs only about $50 per dose and Lucentis costs about $2,000 per injection.

View Full Article in:

Miami Herald (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA